PER
Click for more information
1.23% 8.0¢ percheron therapeutics limited

soon to report on phase iia ms trial, page-12

  1. faimac
    9 Posts.
    clock Created with Sketch.
    01/07/08
    09:49
    Post #: 3930641
    sis Pharmaceuticals Conference Call Notice
    Title: Isis Pharmaceuticals Conference Call Notice
    Description : Isis Pharmaceuticals (Nasdaq: ISIS) will conduct a conference call at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, July 1, to discuss results of the TV-1102 clinical trial and the ATL
    Keywords : CA, Isis, Pharm, Call

    ANP Price at posting: 0.0¢ Sentiment: Buy Disclosure: Held
    Likes Created with Sketch.  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

SKS SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
right-arrow Created with Sketch.
RNU Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
right-arrow Created with Sketch.
AUG Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree
right-arrow Created with Sketch.
FWD Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
right-arrow Created with Sketch.
OBM Ora Banda sees FY26 gold output jumping to 150Koz/pa following key approval for Sand King
right-arrow Created with Sketch.
IMM Immutep reports strong response rate from immunotherapies treating carcinomas
right-arrow Created with Sketch.
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.0¢ 		Change
-0.001(1.23%) 		Mkt cap ! $72.12M
Open High Low Value Volume
8.2¢ 8.2¢ 8.0¢ $63.52K 777.8K

Buyers (Bids)

No. Vol. Price($)
2 43377 8.0¢
 

Sellers (Offers)

Price($) Vol. No.
8.2¢ 97561 1
View Market Depth
Last trade - 16.10pm 12/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.